Q32 Bio

Q32 Bio

Developing therapies targeting powerful regulators of innate and adaptive immunity to rebalance the immune system in severe autoimmune and inflammatory diseases.

HQ location
Cambridge, United States
Website
q32bio.com
Launch date
Employees
11-50 people
Enterprise value
$300m
Jobs
View job openings
Recent deals
https://twitter.com/q32biohttps://www.linkedin.com/company/q32-bio-inc
    • Edit
Get premium to view all results
DateInvestorsAmountRound
investor investor investor investor investor

€0.0

round
investor investor

€0.0

round
investor investor investor investor investor investor investor investor investor

€0.0

Valuation: €0.0

round
N/A

€0.0

round
*

$42.0m

Post IPO Equity
Total Funding000k
Atlas Venture
Atlas Venture
OrbiMed
OrbiMed
Abingworth
Abingworth
Sanofi Ventures
Sanofi Ventures
Colorado Center for Innovation
Colorado Center for Innovation(exited)
Acorn Bioventures
Acorn Bioventures(exited)
Bristol-Myers Squibb
Bristol-Myers Squibb
Osage University Partners
Osage University Partners(exited)
Agent Capital
Agent Capital
CU Healthcare Innovation Fund
CU Healthcare Innovation Fund(exited)
Homology Medicines
Homology Medicines
Osage Univ. Partners
Osage Univ. Partners

Related Content

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Q32 Bio

Edit
Homology Medicines
Homology Medicines
ACQUISITION by Q32 Bio Nov 2023